104325-55-5

Basic information

• Product Name: [3-(QUINOLIN-2-YLMETHOXY)-PHENYL]-ACETIC ACID
• Synonyms: [3-(QUINOLIN-2-YLMETHOXY)-PHENYL]-ACETIC ACID;3-(2-quinolinylmethoxy)benzeneacetic acid;Wy-46016
• CAS NO: 104325-55-5
• Molecular Formula: C₁₈H₁₅NO₃
• Molecular Weight: 293.3166
• Mol File: 104325-55-5.mol

Chemical Properties

• Boiling Point: 500°Cat760mmHg
• Flash Point: 256.2°C
• Appearance: /
• Density: 1.281g/cm³
• Vapor Pressure: 8.12E-11mmHg at 25°C
• Refractive Index: 1.659
• CAS DataBase Reference: [3-(QUINOLIN-2-YLMETHOXY)-PHENYL]-ACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: [3-(QUINOLIN-2-YLMETHOXY)-PHENYL]-ACETIC ACID(104325-55-5)
• EPA Substance Registry System: [3-(QUINOLIN-2-YLMETHOXY)-PHENYL]-ACETIC ACID(104325-55-5)

Safety Data

• Hazardous Substances Data: 104325-55-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Applications:
[3-(QUINOLIN-2-YLMETHOXY)-PHENYL]-ACETIC ACID is used as a potential pharmaceutical agent due to its structural similarity to known bioactive molecules. Its unique chemical structure may contribute to various therapeutic applications, making it an interesting target for the development of new drugs.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, [3-(QUINOLIN-2-YLMETHOXY)-PHENYL]-ACETIC ACID is used as a subject of study for its potential biological activities and chemical properties. Researchers may explore its interactions with biological targets and evaluate its efficacy in treating specific diseases or conditions.
Used in Drug Design and Development:
[3-(QUINOLIN-2-YLMETHOXY)-PHENYL]-ACETIC ACID serves as a starting point for drug design and development. Its chemical structure can be modified and optimized to enhance its pharmacological properties, potentially leading to the creation of novel therapeutic agents with improved efficacy and safety profiles.
Used in Chemical Synthesis:
As a synthetic compound, [3-(QUINOLIN-2-YLMETHOXY)-PHENYL]-ACETIC ACID can be used as a building block or intermediate in the synthesis of more complex molecules with specific applications in various industries, including pharmaceuticals, agrochemicals, and materials science.
Used in Analytical Chemistry:
[3-(QUINOLIN-2-YLMETHOXY)-PHENYL]-ACETIC ACID may also find use in analytical chemistry as a reference compound or standard for the development and validation of analytical methods, such as high-performance liquid chromatography (HPLC) or mass spectrometry (MS), which are essential tools in the characterization and quantification of chemical compounds.

InChI:InChI=1/C18H15NO3/c20-18(21)11-13-4-3-6-16(10-13)22-12-15-9-8-14-5-1-2-7-17(14)19-15/h1-10H,11-12H2,(H,20,21)

Upstream product

• 104325-56-6 methyl 3-(2-quinolinylmethoxy)benzeneacetate 
• 4377-41-7 2-Chloromethylquinoline 
• 102-29-4 Resorcinol monoacetate 
• 42058-59-3 3-hydroxy-benzeneacetic acid, methyl ester 

Downstream Products

• 118308-96-6 N-Benzyloxy-2-[3-(quinolin-2-ylmethoxy)-phenyl]-acetamide 
• 118308-94-4 Wy 48,422 
• 118308-97-7 3-[(2-quinolinyl)methoxy]benzeneaceto hydroxamic acid 
• 119514-96-4 N-[(4-Methylphenyl)sulfonyl]-3-(2-quinolinylmethoxy)benzeneethanamide 
• 123723-96-6 N-Methoxy-N-methyl-2-[3-(quinolin-2-ylmethoxy)-phenyl]-acetamide 

Relevant articles and documents

CYANOMETHYLPYRIDINE DERIVATIVES

The present invention relates to new cyanomethylpyridine dervatives of formula I wherein Y represents N or CH;R1 represents hydrogen, fluoro, chloro, difluoro or dichloro; R2 represents hydrogen or C1-4alkyl;n is 0 or 1; p is 0 or 1; A represents a covalent bond or a group of formula -CONHC-H(Ar)-, -NHCH(Ar)-, -S02NHCH(Ar)-,NHCONHCH(Ar) or OCONHCH(Ar),and when p is 1,A can also represent CH(Ar)NH; and AT represents phenyl or phenyl substituted with halogen,C M alkyl, C1-4 alkoxy or trifluoromethyl. These compounds are PAF antagonist and/or 5-lipoxygenase inhibitors.

N- Carboxylic Acids, Hydroxamic Acids, Tetrazoles, and Sulfonyl Carboxamides. Potent Orally Active Leukotriene D4 Antagonists of Novel Structure

Four series of N- compounds were prepared as leukotriene D4 (LTD4) antagonists.In the hydroxamic acid series, methyl 3-(2-quinolinylmethoxy)benzeneacetohydroxamate (Wy-48,422, 20) was the most potent inhibitor of LTD4-induced bronchoconstriction with an oral ED50 of 7.9 mg/kg.Compound 20 was also orally inhibited ovalbumin-induced bronchoconstriction in the guinea pig with an ED50 of 3.6 mg/kg.In vitro, against LTD4-induced contraction of isolated guinea pig trachea pretreated with indomethacin and 1-cysteine, 20 produced a pKB value of 6.08.In the sulfonyl carboxamide series, N--3-(2-quinolinylmethoxy)-benzamide (Wy-49,353, 30) was the most potent antagonist.Compound 30 orally inhibited both LTD4- and ovalbumin-induced bronchoconstriction with ED50s of 0.4 and 20.2 mg/kg, respectively.In vitro, against LTD4-induced contraction of isolated guinea pig trachea, 30 produced a pKB value of 7.78.In the carboxylic acid series, which served as intermediates for the above two series, 3-(2-quinolinylmethoxy)benzeneacetic acid (Wy-46,016, 5) was the most potent inhibitor of LTD4-induced bronchoconstriction (99percent at 25 mg/kg, intraduodenally); however, the pKB for this compound was disappointing (5.79).In the tetrazole series, the most potent inhibitor was 2-methyl>quinoline (Wy-49,451, 41).The respective inhibitory ED50s were 3.0 mg/kg versus LTD4 and 17.5 mg/kg versus ovalbumin.In the isolated guinea pig trachea, 41 produced a pKB value of 6.70.

Certain unsymmetrical quinolinyl ethers having anti-inflammatory and anti-allergic activity

Compounds of the formula: and salts thereof, wherein Ar1 is a nitrogen, sulfur or oxygen heterocyclic ring; Ar is a phenyl ring or a nitrogen, oxygen or sulfur heterocyclic ring; Ar and Ar1 may be fully substituted or less than fully substituted with H, CH3, lower alkyl, aryl, aralkyl, halo, hydroxy, lower alkoxy, CF3, carboxy, alkylcarboxy, arylcarboxy, alkylcarbalkoxy, alkanoyl, formyl, oxo, nitrilo, amino, aminoalkyl, alkylamine, carboxamide, aryloxy, nitro, sulfonyl, sulfonamide, thio, alkylthio, hydroxyalkyl or oxyalkylcarbalkoxy; X= STR1 of up to 2 carbon atoms in the principal chain and up to a total of 4 carbon atoms, STR2 Z is an alkylene chain containing up to 10 carbon atoms in the principal chain and a total of up to 12 carbon atoms and from 0 to 2 double bonds and the said alkylene chain may be attached to Ar through an oxygen, sulfur or amino nitrogen atom, and when n'=2, one of the R substituents may be halogen on an omega carbon of the alkylene chain Z; when n'=1, R is a substituent attached to one of the carbon atoms of Z selected from the group consisting of =O, OR3, SR3, N(R2)2 and R1, --COR4 and when n'=2 one R is previously defined and the additional R is a substituent attached to one of the carbon atoms of Z selected from the group consisting of =O, OR3, SR3, N(R2)2, --COR4, lactone and halo; R1 is H or CH3 ; R2 is H, lower alkyl, aryl or aralkyl; R3 is H, lower alkyl, lower alkanoyl, aryl, aralkyl or substituted aryl in which the substituent is halo, lower alkyl or lower alkoxy; R4 is OR2 or N(R2)2 ; n=0 or 1; n'=1 to 7; and n"=0, 1 or 2.

Quinolinyl benzene hydroxamic acids as anti-inflammatory/antiallergic agents

There are disclosed compounds of the formula STR1 wherein W represents a covalent bond or STR2 X is N or CR2 ; Y is O, S, NR2 or C(R2)2 when n=0, or N or CR2 when n=1 Z is STR3 R1 is hydrog